BELIEF: Phase 2 trial of erlotinib plus bevacizumab for non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, from Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) phase 2 BELIEF clinical trial. BELIEF evaluated erlotinib plus bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without the T790M mutation.

Share this video  
25th September 2015